PM changes
Pick any two versions below to diff them.
- Price
- $197.88 → $196.35(−0.8%)
- Recent events
- Oct 21, 2026: PMI reported Q3 2026 results. Revenue grew 5.5% to $11.4 billion, or 7.1% on an organic basis, and operating income grew 14.1% to $4.9 billion. Reported diluted EPS fell 4.9% to $2.12, and adjusted diluted EPS grew 5.4% to $2.36. Heated tobacco unit shipments grew 1.5% to 41.5 billion units, and US ZYN shipments grew 4.2% to 3.2 billion pouches. PMI guided 2026 adjusted diluted EPS to $8.29 to $8.44. The quarterly dividend is now $1.60 per share, up 8.8%. added: Sep 18, 2026: PMI raised its quarterly dividend by 8.8%, to $1.60 per share from $1.47, an annual rate of $6.40. PMI has raised its dividend every year since it became a public company in 2008. Aug 21, 2026: The FDA authorized 11 ZYN ULTRA products under the premarket tobacco product application process. Jul 22, 2026: PMI reported Q2 2026 results. Revenue was $11.2 billion, and adjusted diluted EPS grew 15.2% to $2.20. Reported diluted EPS was $1.80, after an impairment charge on its investment in RBH in Canada. Jun 30, 2026: The FDA authorized 20 ZYN products as modified risk tobacco products. Jun 29, 2026: PMI paid back €1.0 billion of the euro term loan from the Swedish Match purchase before its due date. About €1.5 billion of the loan is left, due June 23, 2027. May 20, 2026: PMI named Massimo Andolina Chief Financial Officer from August 1, 2026, in place of Emmanuel Babeau. Apr 22, 2026: PMI reported Q1 2026 results. Revenue was $10.1 billion, reported diluted EPS was $1.56 and adjusted diluted EPS grew 16% to $1.96. US results were weak because of changes in ZYN inventory. Feb 6, 2026: PMI reported 2025 results. Revenue was more than $40 billion, reported diluted EPS was $7.26 and adjusted diluted EPS was $7.54. PMI set targets for 2026 to 2028 of organic revenue growth of 6% to 8%, organic operating income growth of 8% to 10% and adjusted EPS growth of 9% to 11% a year at constant currency, and it changed to three new segments.